Anavex Life Sciences has been granted a patent for polymorphic forms of ANAVEX2-73, a compound used in the treatment of Alzheimer’s disease. The patent also covers a method of making these forms by crystallizing ANAVEX2-73 in a supercritical fluid environment using supercritical carbon dioxide. GlobalData’s report on Anavex Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Anavex Life Sciences Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Anavex Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Anavex Life Sciences's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for method of making crystalline forms of anavex2-73

Source: United States Patent and Trademark Office (USPTO). Credit: Anavex Life Sciences Corp

A recently granted patent (Publication Number: US11661405B2) discloses a method for producing different crystalline forms of ANAVEX2-73, a compound with potential therapeutic applications. The method involves crystallizing ANAVEX2-73 in a supercritical fluid (SCF) environment, specifically using supercritical carbon dioxide.

The method described in claim 2 provides more details on the crystallization process. It involves creating a solution of ANAVEX2-73 in a solvent and introducing this solution to the SCF environment. The ANAVEX2-73 then crystallizes within the SCF, forming crystals. These crystals are then isolated, resulting in the desired crystal Form I, Form II, or Form III of ANAVEX2-73.

Claim 3 specifies the various solvents that can be used in the method. These solvents include ethanol, acetonitrile, isopropyl alcohol, trifluoroethanol, acetone, and several others. The use of different solvents allows for flexibility in the crystallization process, potentially influencing the properties of the final crystal forms.

Lastly, claim 4 provides information on the conditions of the SCF environment. The pressure ranges from about 85 bar to about 200 bar, while the temperature is approximately 40°C. These specific conditions are crucial for achieving the desired crystalline forms of ANAVEX2-73.

This patent reveals a novel method for producing different crystalline forms of ANAVEX2-73 using a supercritical fluid environment. The use of supercritical carbon dioxide as the SCF and the inclusion of various solvents offer versatility in the process, potentially leading to different crystal forms with distinct properties. The disclosed method provides a valuable contribution to the field of pharmaceutical research and development, as it allows for the production of ANAVEX2-73 in specific crystal forms, which may have different therapeutic effects.

To know more about GlobalData’s detailed insights on Anavex Life Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies